Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
J Thorac Oncol
.
2022 Oct 14:S1556-0864(22)00349-5.
doi: 10.1016/j.jtho.2022.07.009.
Online ahead of print.
PMID:
36244926
DOI:
10.1016/j.jtho.2022.07.009
No abstract available
Publication types
Published Erratum